Welcome to Critical MassLaw.com’s new briefing on class actions and mass torts. I’m Amanda Bronstad in Los Angeles. All eyes are on Florida, where the state’s highest court is reviewing evidence standards, weighing whether it should shift from Frye to Daubert in evaluating expert testimony. The U.S. Justice Department asked the U.S. Supreme Court to reject a petition to review cy pres–no matter how “regrettable” the payments may be. And AG Jeff Sessions‘ announcement last week that the feds would take legal action against opioid companies came after a months-long court fight involving the DOJ’s position on Drug Enforcement Agency records.

Send your feedback to [email protected], or find me on Twitter: @abronstadlaw.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]